Integra LifeSciences Holdings Corporation (NASDAQ:IART) Stock Has Average Price Target of $18.86

Integra LifeSciences Holdings Corporation (NASDAQ:IART) has been assigned an average recommendation of “Reduce” from the eight analysts that are currently covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a buy rating on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $18.86.

A number of equities analysts have commented on the stock. BMO Capital Markets began coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They set a “market perform” rating and a $19.00 target price on the stock. Wells Fargo & Company increased their price target on shares of Integra LifeSciences from $15.00 to $18.00 and gave the company an “equal weight” rating in a research note on Thursday, July 30th. Argus raised shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Thursday, June 18th. Wall Street Zen cut Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, July 18th. Finally, UBS Group initiated coverage on Integra LifeSciences in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 price objective for the company.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Sequoia Financial Advisors LLC lifted its holdings in shares of Integra LifeSciences by 221.7% in the 2nd quarter. Sequoia Financial Advisors LLC now owns 45,785 shares of the life sciences company’s stock worth $822,000 after acquiring an additional 31,552 shares during the last quarter. WINTON GROUP Ltd purchased a new stake in Integra LifeSciences in the second quarter valued at approximately $1,843,000. Integrated Wealth Concepts LLC acquired a new position in Integra LifeSciences during the second quarter worth $84,000. Corient Private Wealth LP boosted its position in shares of Integra LifeSciences by 66.9% during the second quarter. Corient Private Wealth LP now owns 22,749 shares of the life sciences company’s stock worth $409,000 after buying an additional 9,120 shares during the period. Finally, Wellington Management Group LLP grew its stake in shares of Integra LifeSciences by 12.4% in the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after buying an additional 160,814 shares in the last quarter. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Performance

NASDAQ:IART opened at $15.88 on Friday. The company has a market cap of $1.23 billion, a P/E ratio of -176.42, a P/E/G ratio of 0.82 and a beta of 1.21. Integra LifeSciences has a twelve month low of $8.70 and a twelve month high of $20.49. The company’s 50-day moving average price is $17.09 and its 200-day moving average price is $14.93. The company has a current ratio of 3.60, a quick ratio of 2.11 and a debt-to-equity ratio of 1.75.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The business had revenue of $418.76 million for the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, sell-side analysts forecast that Integra LifeSciences will post 2.46 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery and wound care. Its technologies are designed to help healthcare professionals treat complex conditions, repair damaged tissue and support surgical procedures.

The company’s portfolio includes dural repair products and other neurosurgical implants, surgical instruments, regenerative tissue technologies, wound-care products and solutions for extremity reconstruction.